https://orcid.org/0000-0001-9585-0187
References
- Napso T, Yong HEJ, Lopez-Tello J, et al. The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation. Front Physiol. 2018;9:1091.
- Ladyman SR, Larsen CM, Taylor RS, et al. Case-control study of prolactin and placental lactogen in SGA pregnancies. Reprod Fertil. 2021;2(4):244–250.
- Baud O, Berkane N. Hormonal changes associated with Intra-Uterine growth restriction: Impact on the developing brain and future neurodevelopment. Front Endocrinol. 2019;10:179.
- Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007;27(3):264–271.
- Arnott C, Patel S, Hyett J, et al. Women and cardiovascular disease: pregnancy, the forgotten risk factor. Heart Lung Circ. 2020;29(5):662–667.
- Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
- Herraiz I, Llurba E, Verlohren S, Spanish Group for the Study of Angiogenic Markers in Preeclampsia, et al. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/ PlGF ratio in singleton pregnancies . Fetal Diagn Ther. 2018;43(2):81–89.
- Herraiz I, Dröge LA, Gómez-Montes E, et al. Characterization of the soluble fms-like tyrosine kinase-1 to placental growth factor ratio in pregnancies complicated by fetal growth restriction. Obstet Gynecol. 2014;124(2):265–273.
- Martinez J, Boada D, Figueras F, et al. How to define late fetal growth restriction. Minerva Obstet Gynecol. 2021;73(4):409–414.
- Pérez-López FR, López-Baena MT, Varikasuvu SR, et al. Preeclampsia and gestational hypertension are associated to low maternal circulating kisspeptin levels: a systematic review and meta-analysis. Gynecol Endocrinol. 2021;37(12):1055–1062.
- Armstrong RA, Reynolds RM, Leask R, et al. Decreased serum levels of kisspeptin in early pregnancy are associated with intra-uterine growth restriction and pre-eclampsia. Prenat Diagn. 2009;29(10):982–985.
- Dawid M, Mlyczyńska E, Jurek M, et al. Apelin, APJ, and ELABELA: role in placental function, pregnancy, and foetal development—an overview. Cells. 2021;11(1):99.
- He Y, Chen S, Huang H, et al. Association between decreased plasma levels of soluble human leukocyte antigen-G and severe pre-eclampsia. J Perinat Med. 2016;44(3):283–290.
- Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, et al. Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;258:366–381.
- Gardosi J, Giddings S, Buller S, et al. Preventing stillbirths through improved antenatal recognition of pregnancies at risk due to fetal growth restriction. Public Health. 2014;128(8):698–702.
- Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298(6673):564–567.
- Stotland NE, Caughey AB, Breed EM, et al. Risk factors and obstetric complications associated with macrosomia. Int J Gynaecol Obstet. 2004;87(3):220–226.
- Caradeux J, Martinez-Portilla RJ, Peguero A, et al. Diagnostic performance of third-trimester ultrasound for the prediction of late-onset fetal growth restriction: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019;220(5):449–459.e19.
- Savirón-Cornudella R, Esteban LM, Tajada-Duaso M, et al. Detection of adverse perinatal outcomes at term delivery using ultrasound estimated percentile weight at 35 weeks of gestation: comparison of five fetal growth standards. Fetal Diagn Ther. 2020;47(2):104–114.